

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:)

Carol MORRIS *et al.*)

Application No.: 09/367,009)

Filed: November 8, 1999)

For: DIAGNOSIS OF DISEASE)
USING TEARS)



Group Art Unit: 1642

Examiner: Minh-Tam B. Davis

Commissioner for Patents
Washington, D.C. 20231
BOX SEQUENCE

STATEMENT ACCOMPANYING SEQUENCE LISTING

Dear Sir:

The undersigned hereby states upon information and belief that the Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,
MORGAN, LEWIS & BOCKIUS LLP

Dated: 3/13/01

By: Rosanne Kesson
Printed Name: Rosanne Kesson
Registration No. 46,840

MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, NW
Washington, D.C. 20036
Tel: 202-467-7000
Fax: 202-467-7176

RECEIVED
MAR 16 2001
TECH CENTER 1600/2900

SEQUENCE LISTING

<110> Morris, Carol
 Wilcox, Mark
 Bolis, Shirley
 Walsh, Bradley
 Herbert, Ben
 Molloy, Mark
 Gooley, Andrew Arthur
 Williams, Keith Leslie



<120> Diagnosis of Disease Using Tears

<130> 47763-5010-US

<140> US 09/367,009

<141> 1999-11-08

<150> AU PO5009

<151> 1997-02-07

<150> PCT/AU98/00071

<151> 1998-02-06

<160> 9

<170> PatentIn Ver. 2.1

<210> 1

<211> 27

<212> PRT

<213> Homo sapiens

<220>

<223> Disease marker sequence

<220>

<221> VARIANT

<222> (15)

<223> Glx = Glu or Gln

<400> 1

Glu Asp Ala Ser Ser Asp Ser Thr Gly Ala Asp Pro Ala Gln Glx
 1 5 10 15

Gly Thr Ser Gln Pro Asn Glu Asp Ile Ala Gly
 20 25

RECEIVED

MAR 16 2001

TECH CENTER 1600/2900

<210> 2
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<223> Disease marker sequence

<400> 2
Trp Asp Pro Lys Glu
1 5

B8 contd
<210> 3
<211> 74
<212> PRT
<213> Homo sapiens

<220>
<223> Disease marker sequence

<400> 3
Asp Ser Gly Cys Lys Leu Leu Glu Asp Met Val Glu Lys Thr Ile Asn
1 5 10 15
Ser Asp Ile Ser Ile Pro Glu Tyr Lys Glu Leu Leu Gln Glu Phe Ile
20 25 30
Asp Ser Asp Ala Ala Ala Glu Ala Met Gly Lys Phe Lys Gln Cys Phe
35 40 45
Leu Asn Gln Ser His Arg Thr Leu Lys Asn Phe Gly Leu Met Met His
50 55 60
Thr Val Tyr Asp Ser Ile Trp Cys Asn Leu
65 70

<210> 4
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<223> N terminus of disease marker sequence

<400> 4

Glu Asp Ala Ser Ser
1 5

<210> 5
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<223> N terminus of disease marker sequence

<400> 5
Ser Ser Ser Lys Glu
1 5

<210> 6
<211> 13
<212> PRT
<213> Homo sapiens

<220>
<223> N terminus of disease marker sequence

<400> 6
Asp Ser Gly Cys Lys Leu Leu Glu Asp Met Val Glu Lys
1 5 10

<210> 7
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> N terminus of disease marker sequence

<400> 7
His His Leu Leu Ala Ser Asp Glu Glu
1 5

<210> 8
<211> 4
<212> PRT
<213> Homo sapiens

<220>

<223> N terminus of disease marker sequence

<400> 8

Ser Asp Glu Glu

1

<210> 9

<211> 4

<212> PRT

<213> Homo sapiens

<220>

<223> N terminus of disease marker sequence

<400> 9

Gly Arg Arg Arg

1

B8
Perth